Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 18/20 | 0.60 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.60 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4680304 | 0.78 | MAPK14 (0.45) | MAPK14CSNK1DMAPK9 | |
| SCHEMBL4679157 | 0.73 | MAPK10 (0.58) | MAPK14CSNK1DMAPK8MAPK9 | |
| SCHEMBL14143111 | 0.71 | MAPK10 (0.56) | MAPK14CSNK1DKDRMAPK8MAPK9 | |
| SCHEMBL5818374 | 0.70 | MAPK14 (0.54) | MAPK14CSNK1DEGFRRAF1ERBB2 | |
| SCHEMBL5812796 | 0.70 | MAPK14 (0.71) | MAPK14EGFRRAF1ERBB2KDR | |
| SCHEMBL2848291 | 0.70 | MAPK14 (0.76) | MAPK14 | |
| SCHEMBL2853058 | 0.70 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL4684820 | 0.70 | MAPK10 (0.62) | MAPK14CSNK1DMAPK8MAPK9 | |
| SCHEMBL2847992 | 0.70 | MAPK14 (1.00) | MAPK14 | |
| SCHEMBL5567859 | 0.69 | MAPK14 (0.48) | MAPK14CSNK1DEGFRRAF1ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218369-B1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7169798-B2 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1218369-A4 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | GREEN JEREMY (US) | 2005-02-03 | — | — | US | disclosed |
| US-6693108-B2 | PYRIMIDINYL-GUANIDINE DERIVATIVES | VERTEX PHARMACEUTICALS INCORPORATED | 2004-02-17 | — | — | US | disclosed |
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | VERTX PHARMACEUTICALS INCORPORATED | 2003-08-07 | — | — | US | disclosed |
| EP-1218369-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001012621-A1 | INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149051-A1 | Inhibitors of c-Jun N terminal kinases (JNK) and other protein kinases | MAPK1, PACSIN2, MAP3K1 | MAPK14 48/4885CSNK1D 62/4885EGFR 666/4885 |
| US-20050026967-A1 | Inhibitors of c-jun N terminal kinases (JNK) and other protein kinases | MAP3K2, CSNK1G2, MAP3K5 | MAPK14 43/4885CSNK1D 78/4885EGFR 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.